Inhibitory effect of GLP-1 on gastric motility persists after vagal deafferentation in pigs

References

• Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665–73
   PubMed Web of Science ®Google Scholar
• Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004; 39: 353–8
   PubMed Web of Science ®Google Scholar
• Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515–20
   PubMed Web of Science ®Google Scholar
• Gutzwiller JP, Goke B, Drewe J, Hildebrand P, Ketterer S, Handschin D, et al. Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 1999; 44: 81–6
   PubMed Web of Science ®Google Scholar
• Holst JJ, Orskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett 1987; 211: 169–74
   PubMed Web of Science ®Google Scholar
• Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36: 741–4
   PubMed Web of Science ®Google Scholar
• Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 (proglucagon-(78-107) amide) on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123: 2009–13
   PubMed Web of Science ®Google Scholar
• Hoosein NM, Gurd RS. Identification of glucagon receptors in rat brain. Proc Natl Acad Sci USA 1984; 81: 4368–72
   PubMedGoogle Scholar
• Blazquez E, Alvarez E, Navarro M, Roncero I, Rodriguez-Fonseca F, Chowen JA, et al. Glucagon-like peptide-1 (7-36) amide as a novel neuropeptide. Mol Neurobiol 1998; 18: 157–73
   PubMedGoogle Scholar
• Merida E, Delgado E, Molina LM, Villanueva-Penacarrillo ML, Valverde I. Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 1993; 77: 1654–7
   PubMed Web of Science ®Google Scholar
• Orskov C, Poulsen SS. Glucagonlike peptide-I-(7-36)-amide receptors only in islets of Langerhans. Autoradiographic survey of extracerebral tissues in rats. Diabetes 1991; 40: 1292–6
   PubMedGoogle Scholar
• Richter G, Goke R, Goke B, Schmidt H, Arnold R. Characterization of glucagon-like peptide-I(7-36)amide receptors of rat lung membranes by covalent cross-linking. FEBS Lett 1991; 280: 247–50
   PubMed Web of Science ®Google Scholar
• Shimizu I, Hirota M, Ohboshi C, Shima K. Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 1987; 121: 1076–82
   PubMed Web of Science ®Google Scholar
• Uttenthal LO, Toledano A, Blazquez E. Autoradiographic localization of receptors for glucagon-like peptide-1 (7-36) amide in rat brain. Neuropeptides 1992; 21: 143–6
   PubMed Web of Science ®Google Scholar
• Holst JJ. Enteroglucagon. Annu Rev Physiol 1997; 59: 257–71
   PubMed Web of Science ®Google Scholar
• Holz GG, Kuhtreiber WM, Habener JF. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 1993; 361: 362–5
   PubMed Web of Science ®Google Scholar
• Layer P, Holst JJ, Grandt D, Goebell H. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40: 1074–82
   PubMed Web of Science ®Google Scholar
• Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997; 40: 597–601
   PubMed Web of Science ®Google Scholar
• Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275: G984–92
   PubMedGoogle Scholar
• Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273: G920–7
   PubMed Web of Science ®Google Scholar
• Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110: 36–43
   PubMed Web of Science ®Google Scholar
• Ionut V, Hucking K, Liberty IF, Bergman RN. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 2005; 48: 967–75
   PubMedGoogle Scholar
• Giralt M, Vergara P. Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat. Regul Pept 1998; 74: 19–25
   PubMedGoogle Scholar
• Darcy B, Falempin M, Laplace JP, Rousseaue JP. Importance de la voie vagale sensitive: Recherche d'une technique de déafférentation sélective chez le porc et le mouton. Ann Biol Anim Bioch Biophys 1979; 19: 881–8
   Google Scholar
• Laplace JP. Gastric motility in the pig after surgical interruption of vagal afferent pathways. 78; 5th Int Pig Vet Soc Congress, Zagreb, KA 44: 1978.
   Google Scholar
• Holst JJ, Schaffalitzky de Muckadell OB, Fahrenkrug J. Nervous control of pancreatic exocrine secretion in pigs. Acta Physiol Scand 1979; 105: 33–51
   PubMedGoogle Scholar
• Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 1994; 43: 535–9
   PubMed Web of Science ®Google Scholar
• Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995; 80: 952–7
   PubMed Web of Science ®Google Scholar
• McTigue DM, Hermann GE, Rogers RC. Effect of pancreatic polypeptide on rat dorsal vagal complex neurons. J Physiol 1997; 499: 475–83
   PubMed Web of Science ®Google Scholar
• Rogers RC, McTigue DM, Hermann GE. Vagal control of digestion: modulation by central neural and peripheral endocrine factors. Neurosci Biobehav Rev 1996; 20: 57–66
   PubMed Web of Science ®Google Scholar
• Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7: 2294–300
   PubMed Web of Science ®Google Scholar
• Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 1996; 45: 832–5
   PubMed Web of Science ®Google Scholar
• Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271: R848–56
   PubMed Web of Science ®Google Scholar
• Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding [see comments]. Nature 1996; 379: 69–72
   PubMed Web of Science ®Google Scholar
• Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 1998; 47: 530–7
   PubMedGoogle Scholar
• Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998; 43: 2284–90
   PubMedGoogle Scholar
• Miholic J, Orskov C, Holst JJ, Kotzerke J, Meyer HJ. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 1991; 36: 1361–70
   PubMed Web of Science ®Google Scholar